Literature DB >> 11181459

Polymorphic variation in CYP19 and the risk of breast cancer.

S W Baxter1, D Y Choong, D M Eccles, I G Campbell.   

Abstract

The production of estrogen from androgen via the estrogen biosynthesis pathway is catalyzed by aromatase P450 (cyp19). We have assessed the frequency of allelic variants of the CYP19 intron 4 [TTTA]n repeat in 327 breast cancer cases and 253 controls from southern England. Previous studies have suggested that the [TTTA](10) repeat and [TTTA](12) repeat variants represent low penetrance breast cancer susceptibility alleles. Compared with controls our breast cancer cases had a statistically significant positive association with the [TTTA](10) allele (1.5 versus 0.2%, P = 0.028) and the [TTTA](8) allele (13.5 versus 8.7%, P = 0.012). The frequency of the [TTTA](12) allele was not significantly elevated in our study group compared with controls (2.3 versus 2.2%, P = 1.00). The CYP19 intron 4 [TTTA]n repeat is unlikely to have a functional effect on aromatase activity and it is more likely that the [TTTA](8) and [TTTA](10) variants are in linkage disequilibrium with other functional CYP19 variants.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11181459     DOI: 10.1093/carcin/22.2.347

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  17 in total

1.  Polymorphisms of estrogen-biosynthesis genes CYP17 and CYP19 may influence age at menarche: a genetic association study in Caucasian females.

Authors:  Yan Guo; Dong-Hai Xiong; Tie-Lin Yang; Yan-Fang Guo; Robert R Recker; Hong-Wen Deng
Journal:  Hum Mol Genet       Date:  2006-06-16       Impact factor: 6.150

2.  A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.

Authors:  Janet E Olson; James N Ingle; Cynthia X Ma; Linda L Pelleymounter; Daniel J Schaid; V Shane Pankratz; Robert A Vierkant; Zachary S Fredericksen; Yanhong Wu; Fergus J Couch; Celine M Vachon; Thomas A Sellers; Richard M Weinshilboum
Journal:  Breast Cancer Res Treat       Date:  2006-09-27       Impact factor: 4.872

3.  Novel pathway analysis of genomic polymorphism-cancer risk interaction in the Breast Cancer Prevention Trial.

Authors:  Barbara K Dunn; Mark H Greene; Jenny M Kelley; Joseph P Costantino; Robert J Clifford; Ying Hu; Gong Tang; Neely Kazerouni; Philip S Rosenberg; Daoud M Meerzaman; Kenneth H Buetow
Journal:  Int J Mol Epidemiol Genet       Date:  2010-09-05

4.  Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Authors:  Michele L Cote; Wonsuk Yoo; Angela S Wenzlaff; Geoffrey M Prysak; Susan K Santer; Gina B Claeys; Alison L Van Dyke; Susan J Land; Ann G Schwartz
Journal:  Carcinogenesis       Date:  2009-01-27       Impact factor: 4.944

5.  An aromatase polymorphism modulates the relationship between weight and estradiol levels in obese men.

Authors:  Ahmad Hammoud; Douglas T Carrell; A Wayne Meikle; Yuanpei Xin; Steven C Hunt; Ted D Adams; Mark Gibson
Journal:  Fertil Steril       Date:  2009-12-11       Impact factor: 7.329

6.  A polymorphism at the 3'-UTR region of the aromatase gene defines a subgroup of postmenopausal breast cancer patients with poor response to neoadjuvant letrozole.

Authors:  Zaida Garcia-Casado; Angel Guerrero-Zotano; Antonio Llombart-Cussac; Ana Calatrava; Antonio Fernandez-Serra; Amparo Ruiz-Simon; Joaquin Gavila; Miguel A Climent; Sergio Almenar; Jose Cervera-Deval; Josefina Campos; Carlos Vazquez Albaladejo; Antonio Llombart-Bosch; Vicente Guillem; Jose A Lopez-Guerrero
Journal:  BMC Cancer       Date:  2010-02-09       Impact factor: 4.430

7.  Variants in hormone biosynthesis genes and risk of endometrial cancer.

Authors:  Sara H Olson; Irene Orlow; Sharon Bayuga; Camelia Sima; Elisa V Bandera; Katherine Pulick; Shameka Faulkner; Diana Tommasi; Daniel Egan; Pampa Roy; Homer Wilcox; Ali Asya; Ippolito Modica; Haider Asad; Robert Soslow; Ann G Zauber
Journal:  Cancer Causes Control       Date:  2008-04-25       Impact factor: 2.506

8.  Haplotype analyses of CYP19A1 gene variants and breast cancer risk: results from the Shanghai Breast Cancer Study.

Authors:  Qiuyin Cai; Nobuhiko Kataoka; Chun Li; Wanqing Wen; Jeffrey R Smith; Yu-Tang Gao; Xiao Ou Shu; Wei Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-01       Impact factor: 4.254

9.  Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors.

Authors:  Liewei Wang; Katarzyna A Ellsworth; Irene Moon; Linda L Pelleymounter; Bruce W Eckloff; Yvette N Martin; Brooke L Fridley; Gregory D Jenkins; Anthony Batzler; Vera J Suman; Saranya Ravi; J Michael Dixon; William R Miller; Eric D Wieben; Aman Buzdar; Richard M Weinshilboum; James N Ingle
Journal:  Cancer Res       Date:  2010-01-01       Impact factor: 12.701

10.  Genetic variation in CYP19A1 and risk of breast cancer and fibrocystic breast conditions among women in Shanghai, China.

Authors:  Chu Chen; Lori C Sakoda; Jennifer A Doherty; Melissa M Loomis; Sherianne Fish; Roberta M Ray; Ming Gang Lin; Wenhong Fan; Lue Ping Zhao; Dao Li Gao; Helge Stalsberg; Ziding Feng; David B Thomas
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2008-12       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.